Australia's most trusted
source of pharma news
Friday, 01 August 2025
Posted 30 July 2025 AM
Big Pharma faces over US$300 billion in potential lost sales due to patent expiries over the next five years – and five companies are most at risk.
The staggering figures released in Evaluate’s latest report, represents three to four per cent of the overall market, with a bump in 2028 to almost seven per cent due to Keytruda’s anticipated loss.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.